Schistosomiasis and soil-transmitted helminthiasis: Common drugs for treatment and control

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 263-285

  Utzinger, Jürg ^a   Keiser, Jennifer ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

Albendazole; Artemisinin derivatives; Chemotherapy; Ivermectin; Levamisole; Mebendazole; Oxamniquine; Piperazine; Praziquantel; Pyrantel pamoate; Schistosomiasis; Soil transmitted helminthiasis (STH); Tribendimidine

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFONE; ALBENDAZOLE SULFOXIDE; AMPICILLIN; ANTHELMINTIC AGENT; ANTIPARASITIC AGENT; ANTISCHISTOSOMAL AGENT; ARTEMETHER; ARTEMISIN DERIVATIVE; ARTESUNATE; BENZIMIDAZOLE DERIVATIVE; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450; DIHYDROARTEMISININ; DRUG METABOLITE; FLAVINE MONONUCLEOTIDE REDUCTASE; IVERMECTIN; LEVAMISOLE; MEBENDAZOLE; NITAZOXANIDE; OXAMNIQUINE; OXANTEL; OXIBENDAZOLE; PIPERAZINE; PLACEBO; PRAZIQUANTEL; PYRANTEL EMBONATE; PYRAZINOIC ACID DERIVATIVE; UNINDEXED DRUG;

ABDOMINAL PAIN; AFRICA; ANOREXIA; ANTIBIOTIC RESISTANCE; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COST OF ILLNESS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; DISEASE TRANSMISSION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; ENCEPHALITIS; EPIGASTRIC PAIN; EPILEPSY; FATIGUE; FEVER; FOOD DRUG INTERACTION; GEOGRAPHIC DISTRIBUTION; HEADACHE; HELMINTHIASIS; HUMAN; INCIDENCE; INFECTION CONTROL; INTESTINE PARASITE; LIVER DYSFUNCTION; LOWEST INCOME GROUP; MALARIA; MENTAL DISEASE; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MYASTHENIA GRAVIS; NAUSEA; NEMATODE; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARASITISM; PARESTHESIA; PRURITUS; PUBLIC HEALTH; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS; SINGLE DRUG DOSE; SKIN EDEMA; SOIL; TREATMENT PLANNING; TREMATODE; URTICARIA; VOMITING; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTHELMINTICS; CLINICAL TRIALS; DISEASE RESERVOIRS; HELMINTHIASIS; HUMANS; MULTICENTER STUDIES; SCHISTOSOMIASIS; SOIL MICROBIOLOGY;

EID: 1242296814     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.263     Document Type: Review

References (187)

1. WHO: Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Tech. Rep. Set. No. 912, World Health Organization, Geneva (2002).
2. SAVIOLI L, STANSFIELD S, BUNDY DAP et al.: Schistosomiasis and soil-transmitted helminth infections: forging control efforts. Trans. R. Soc. Trop. Med. Hyg. (2002) 96:577-579.
3. CROMPTON DWT, NESHEIM MC: Nutritional impact of intestinal helminthiasis during the human life cycle. Ann. Rev. Nutr. (2002) 22:35-59.
4. AWASTHI S, BUNDY DAP, SAVIOLI L: Helminthic infections. Br. Med. J. (2003) 327:431-433.
5. MIGUEL E, KREMER M: Worms: identifying impacts on education and health in the presence of treatment externalities. Econometrica (2004) 72:159-217.
6. BERGQUIST R, AL-SHERBINY M, BARAKAT R, OLDS R: Blueprint for schistosomiasis vaccine development. Acta Trop. (2002) 82:183-192.
7. HOTEZ PJ, ZHAN B, BETHONY JM et al.: Progress in the development of a recombinant vaccine for human hookworm disease: the human hookworm vaccine initiative. Int. J. Parasitol. (2003) 33:1245-1258.
8. WHO: The control of schistosomiasis: report of a WHO expert committee. WHO Tech. Rep. Ser. No. 728, World Health Organization, Geneva (1985).
9. WHO: Report of an informal consultation on intestinal helminths. WHO/CDS/IPI/90.1, World Health Organization, Geneva (1990).
10. DE SILVA NR: Impact of mass chemotherapy on the morbidity due to soil-transmitted nematodes. Acta Trop. (2003) 86:197-214.
11. RICHTER J: The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop. (2003) 86:161-183.
12. PARTNERSHIP FOR CHILD DEVELOPMENT: The cost of large-scale school health programmes which deliver anthelmintics to children in Ghana and Tanzania. Acta Trop. (1999) 73:183-204.
13. BERGQUIST NR: Schistosomiasis: from risk assessment to control. Trends Parasitol. (2002) 18:309-314.
14. FENWICK A, SAVIOLI L, ENGELS D, BERGQUIST NR, TODD MH: Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol. (2003) 19:509-515.
15. GUYATT H: The cost of delivering and sustaining a control programme for schistosomiasis and soil-transmitted helminthiasis. Acta Trop. (2003) 86:267-274.
16. URBANI C, ALBONICO, M: Anthelminthic drug safety and drug administration in the control of soil-transmitted helminthiasis in community campaigns. Acta Trop. (2003) 86:215-221.
17. SCHAD GA, ROZEBOOM LE: Integrated control of helminths in human populations. Ann. Rev. Ecol. Syst. (1976) 7:393-420.
18. DAVIS A: Schistosomiasis. In: Manson's Tropical Diseases (21st edn). Cook GC, Zumla AI (Eds.), WB Saunders, Philadelphia, USA (2003):1431-1469.
19. HORTON J: Global anthelmintic chemotherapy programs: learning from history. Trends Parasitol. (2003) 19:405-409.
20. UTZINGER J, BERGQUIST R, XIAO SH, SINGER BH, TANNER M: Sustainable schistosomiasis control - the way forward. Lancet (2003) 362:1932-1934.
21. CHITSULO L, ENGELS D, MONTRESOR A, SAVIOLI L: The global status of schistosomiasis and its control. Acta Trop. (2000) 77:41-51.
22. ENGELS D, CHITSULO L, MONTRESOR A, SAVIOLI L: The global epidemiological situation of schistosomiasis and new approaches to control and research: Acta Trop. (2002) 82:139-146.
23. TCHUEM TCHUENTE L-A, SOUTHGATE VR, JOURDANE J, WEBSTER BL, VERCRUYSSE J: Schistosoma intercalatum: an endangered species in Cameroon? Trends Parasitol. (2003) 19:389-393.
24. PATZ JA, GRACZYK TK, GELLER N, VITTOR AY: Effects of environmental change on emerging parasitic diseases. Int. J. Parasitol. (2000) 30:1395-1405.
25. ROSS AGP, BARTLEY PM, SLEIGH AC et al.: Schistosomiasis. N. Engl. J. Med. (2002) 346:1212-1220.
26. HU W, YAN Q, SHEN DK et al.: Evolutionary and biomedical implications of a Schistosoma japonicum complementary DNA resource. Nat. Genet. (2003) 35:139-147.
27. ASH LR, ORIHEL TC, SAVIOLI L: Bench aids for the diagnosis of intestinal parasites. World Health Organization, Geneva (1994).
28. HATZ CFR: The use of ultrasound in schistosomiasis. Adv. Parasitol. (2001) 48:225-284.
29. RICHTER J, HATZ C, HAUSSINGER D: Ultrasound in tropical and parasitic diseases. Lancet (2003) 362:900-902.
30. VAN DER WERF MJ, DE VLAS SJ, BROOKER S et al.: Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. (2003) 86:125-139.
31. DE SILVA NR, BROOKER S, HOTEZ PJ, MONTRESOR A, ENGELS D, SAVIOLI L: Soil-transmitted helminth infections: updating the global picture. Trends Parasitol. (2003) 19:547-551.
32. STOLL NR: This wormy world. J. Parasitol. (1947) 33:1-18.
33. CHAN MS, MEDLEY GF, JAMISON D, BUNDY DAP: The evaluation of potential global morbidity attributable to intestinal nematode infections. Parasitology (1994) 109:373-387.
34. BORKOW G, WEISMAN Z, LENG Q et al.: Helminths, human immunodeficiency virus and tuberculosis. Scand. J. Infect. Dis. (2001) 33:568-571.
35. WHO: The use of essential drugs. WHO Tech. Rep. Ser. No. 867, World Health Organization, Geneva, 1997.
36. HAGAN P, APPLETON CC, COLES GC, KUSEL JR, TCHUEM-TCHUENTÉ L-A: Schistosomiasis control: keep taking the tablets. Trends Parasitol. (2004) 20:92-97.
37. UTZINGER J, XIAO SH, N'GORAN EK, BERGQUIST R, TANNER M: The potential of artemether for the control of schistosomiasis. Int. J. Parasitol. (2001) 31:1549-1562.
38. XIAO SH, TANNER M, N'GORAN EK et al.: Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop. (2002) 82:175-181.
39. GROLL E: Praziquantel. Adv. Pharmacol. Chemother. (1984) 20:219-238.
40. GÖNNERT R, ANDREWS P: Praziquantel, a new broad-spectrum antischistosomal agent. Z. Parasitenkd. (1977) 52:129-150.
41. PELLEGRINO J, LIMA-COSTA FF, CARLOS MA, MELLO RT: Experimental chemotherapy of schistosomiasis mansoni. XIII. Activity of praziquantel, an isoquinoline-pyrazino derivative, on mice, hamsters and Cebus monkeys. Z. Parasitenkd. (1977) 52:151-168.
42. WEBBE G, JAMES C: A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei im hamsters. Z. Parasitenkd. (1977) 52:169-177.
43. JAMES C, WEBBE G, NELSON GS: The susceptibility to praziquantel of Schistosoma haematobium in the baboon (Papio anubis) and of S. japonicum in the vervet monkey (Cercopithecus aethiops). Z. Parasitenkd. (1977) 52:179-194.
44. KATZ N, ROCHA RS, CHAVES A: Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull. World Health Organ. (1979) 57:781-785.
45. DAVIS A, BILES JE, ULRICH AM: Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull. World Health Organ. (1979) 57:773-779.
46. SANTOS AT, BLAS BL, NOSENAS JS et al.: Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. Bull. World Health Organ. (1979) 57:793-799.
47. LEOPOLD G, UNGETHUM W, GROLL E, DIEKMANN HW, NOWAK H, WEGNER DH: Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur. J. Clin. Pharmacol. (1978) 14:281-291.
48. CASTRO N, MEDINA R, SOTELO J, JUNG H: Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother. (2000) 44:2903-2904.
49. MANDOUR ME, EL TURABI H, HOMEIDA MM et al.: Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans. R. Soc. Trop. Med. Hyg. (1990) 84:389-393.
50. 2+ channel. Int. J. Parasitol. (2003) 33:1303-1308.
51. 2+ channel β subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel. Parasitology (2003) 127:349-356.
52. VALLE C, TROIANI AR, FESTUCCI A et al.: Sequence and level of endogenous expression of calcium channel β subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol. Biochem. Parasitol. (2003) 130:111-115.
53. CIOLI D, PICA-MATTOCCIA L: Praziquantel. Parasitol. Res. (2003) 90:S3-S9.
54. RASO G, N'GORAN EK, TOTY A et al.: Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire. Trans. R. Soc. Trop. Med. Hyg. (2004) 98:18-27.
55. ALLEN HE, CROMPTON DWT, DE SILVA N, LOVERDE PT, OLDS GR: New policies for using anthelmintics in high risk groups. Trends Parasitol, (2002) 18:381-382.
56. HALL A, NOKES C, WEN ST et al.: Alternatives to bodyweight for estimating the dose of praziquantel needed to treat schistosomiasis. Trans. R. Soc. Trop. Med. Hyg. (1999) 93:653-658.
57. MONTRESOR A, ENGELS D, CHITSULO L, BUNDY DAP, BROOKER S, SAVIOLI L: Development and validation of a 'tablet pole' for the administration of praziquantel in sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg. (2001) 95:542-544.
58. MONTRESOR A, ENGELS D, RAMSAN M, FOUM A, SAVIOLI L: Field test of the 'dose pole' for praziquantel in Zanzibar. Trans. R. Soc. Trop. Med. Hyg. (2002) 96:323-324.
59. SABAH AA, FLETCHER C, WEBBE G, DOENHOFF MJ: Schistosoma mansoni: chemotherapy of infections of different ages. Exp. Parasitol. (1986) 61:294-303.
60. RENGANATHAN E, CIOLI D: An international initiative on praziquantel use. Parasitol. Today (1998) 14:390-391.
61. PICQUET M, VERCRUYSSE J, SHAW DJ, DIOP M, LY A: Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans. R. Soc. Trop. Med. Hyg. (1998) 92:90-93.
62. UTZINGER J, N'GORAN EK, N'DRI A, LENGELER C, TANNER M: Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop. Med. Int. Health (2000) 5:771-778.
63. N'GORAN EK, GNAKA HN, TANNER M, UTZINGER J: Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire. Ann. Trop. Med. Parasitol. (2003) 97:37-51.
64. CIOLI D: Praziquantel: is there real resistance and are there alternatives? Curr. Opin. Infect. Dis. (2000) 13:659-663.
65. DANSO-APPIAH A, DE VLAS SJ: Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol. (2002) 18:125-129.
66. DOENHOFF MJ, KUSEL JR, COLES GC, CIOLI D: Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans. R. Soc. Trop. Med. Hyg. (2002) 96:465-469.
67. RICHARDS HC, FOSTER R: A new series of 2-aminomethyltetrahydroquinoline derivatives displaying schistosomicidal activity in rodents and primates. Nature (1969) 222:581-582.
68. DA SILVA LC, SETTE H, CHAMONE DAF, SAEZ ALQUEZAR A, PUNSKAS JA, RAIA S: Clinical trials with oral oxamniquine (UK 4271) for the treatment of mansonian schistosomiasis. Rev. Inst. Med. Trop. Sao Paulo (1974) 16:103-109.
69. KOKWARO GO, TAYLOR G: Oxamniquine pharmacokinetics in healthy Kenyan African volunteers. East Afr. Med. J. (1991) 68:359-364.
70. CIOLI D, PICA-MATTOCCIA L, ARCHER S: Antischistosomal drugs: past, present ... and future? Pharmacol. Ther. (1995) 68:35-85.
71. FOSTER R: A review of clinical experience with oxamniquine. Trans. R. Soc. Trop. Med. Hyg. (1987) 81:55-59.
72. KATZ N: Schistosomiasis control in Brazil. Mem. Inst. Oswaldo Cruz (1998) 93(Suppl. 1):33-35.
73. BECK L, FAVRE TC, PIERI OS, ZANI LC, DOMAS GG, BARBOSA CS: Replacing oxamniquine by praziquantel against Schistosoma mansoni infection in a rural community from the sugar-cane zone of northeast Brazil: an epidemiological follow-up. Mem. Inst. Oswaldo Cruz (2001) 96(Suppl.):165-167.
74. LI Y, WU YL: An over four millennium story behind qinghaosu (artemisinin) - a fantastic antimalarial drug from a traditional chinese herb. Curr. Med. Chem. (2003) 10:2197-2230.
75. GUERIN PJ, OLLIARO P, NOSTEN F et al.: Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect. Dis. (2002) 2:564-573.
76. CHEN DJ, FU LF, SHAO PP et al.: Experimental studies on antischistosomal activity of qinghaosu. Zhong. Hui. Yi. Xue. Zha. Zhi. (1980) 60:422-425.
77. LE W, YOU J, YANG Y et al.: Studies on the efficacy of artemether in experimental schistosomiasis. Acta Pharmaceut. Sin. (1982) 17:187-193.
78. LE WJ, YOU JQ, MEI JY: Chemotherapeutic effect of artesunate in experimental schistosomiasis. Acta Pharmaceut. Sin. (1983) 18:619-621.
79. VAN AGTMAEL MA, EGGELTE TA, VAN BOXTEL CJ: Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol. Sci. (1999) 20:199-205.
80. KARBWANG J, NA-BANGCHANG K, THANAVIBUL A, MOLUNTO P: Plasma concentrations of artemether and its major plasma metabolite, dihydroartemisinin, following a 5-day regimen of oral artemether, in patients with uncomplicated falciparum malaria. Ann. Trop. Med. Parasitol. (1998) 92:31-36.
81. ABDEL AZIZ SS, EL-BADAWY NM: Experimental trials of an artemisinin derivative in treatment of Schistosoma mansoni infected mice. J. Egypt. Soc. Parasitol. (2000) 30:295-303.
82. XIAO SH, WU YL, TANNER M et al.: Schistosoma japonicum: In vitro effects of artemether combined with haemin depend on cultivation media and appraisal of artemether products appearing in the media. Parasitol. Res. (2003) 89:459-466.
83. ECKSTEIN-LUDWIG U, WEBB RJ, VAN GOETHEM IDA et al.: Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 424:957-961.
84. HU SY, LIU J, WANG B, HU ZD, XIAO CJ: The effect of artesunate in preventing the populations from Schistosoma japonicum infection during flood-control. Chin. J. Parasitol. Parasit. Dis. (2000) 18:113-114.
85. UTZINGER J, N'GORAN EK, N'DRI A, LENGELER C, XIAO SH, TANNER M: Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet (2000) 355:1320-1325.
86. BORRMANN S, SZLEZÁK N, FAUCHER J-F et al.: Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J. Infect. Dis. (2001) 184:1363-1366.
87. DE CLERCQ D, VERCRUYSSE J, KONGS A, VERLÉ P, DOMPNIER JP, FAYE PC: Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Trop. (2002) 82:61-66.
88. N'GORAN EK, UTZINGER J, GNAKA HN et al.: Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of parent Schistosoma haematobium infections. Am. J. Trop. Med. Hyg. (2003) 68:24-32.
89. XIAO SH, YAO JM, UTZINGER J, CAI Y, CHOLLET J, TANNER M: Selection and reversal of Plasmodium, berghei resistance in the mouse model following repeated high doses of artemether. Parasitol. Res. (2004) (In Press).
90. DAVIS A, BAILEY DR: Metrifonate in urinary schistosomiasis. Bull. World Health Organ. (1969) 41:209-224.
91. WHO: The control of schistosomiasis: second report of the WHO expert committee. WHO Tech. Rep. Se.r No. 830, World Health Organization, Geneva (1993).
92. CIOLI D: Chemotherapy of schistosomiasis: an update. Parasitol. Today (1998) 14:418-422.
93. FELDMEIER H, CHITSULO L: Therapeutic and operational profiles of metrifonate and praziquantel in Schistosoma haematobium infection. Arzneimittelforschung (1999) 49:557-565.
94. GUYATT HL: Medicinal merits of myrrh. Trends Parasitol. (2002) 18:202.
95. SHEIR Z, NASR AA, MASSOUD A et al.: A safe, effective, herbal antischistosomal therapy derived from myrrh. Am. J. Trop. Med. Hyg. (2001) 65:700-704.
96. VAN DEN BOSSCHE H, ROCHETTE F, HÖRIG C: Mebendazole and related anthelmintics. Adv. Pharmacol. Chemother. (1982) 19:67-128.
97. DE SILVA N, GUYATT H, BUNDY D: Anthelmintics. A comparative review of their clinical pharmacology. Drugs (1997) 53:769-788.
98. BROWN HD, MATZUK AR, ILVES IR et al.: Antiparasitic drugs. IV. 2-(4′-thiazolyl)-benzimidazole, a new anthelmintic. J. Am. Chem. Soc. (1961) 83:1764-1765.
99. MARTIN RJ, ROBERTSON AP, BJORN H: Target sites of anthelmintics. Parasitology (1997) 114:S111-S124.
100. THEODORIDES VJ, CHANG J, DICUOLLO CJ, GRASS GM, PARISH RC, SCOTT GC: Oxibendazole, a new broad spectrum anthelmintic effective against gastrointestinal nematodes of domestic animals. Br. Vet. J. (1973) 129:R97-R98.
101. THEODORIDES VJ, NAWALINSKI T, MURPHY J, FREEMAN J: Efficacy of albendazole against gastrointestinal nematodes of cattle. Am. J. Vet. Res. (1976) 37:1517-1518.
102. HORTON J: Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr. Opin. Infect. Dis. (2002) 15:599-608.
103. DAYAN AD: Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. (2003) 86:141-159.
104. EDWARDS G, BRECKENRIDGE AM: Clinical pharmacokinetics of anthelmintic drugs. Clin. Pharmacokinet. (1988) 15:67-93.
105. MERINO G, MOLINA AJ, GARCIA JL, PULIDO MM, PRIETO JG, ALVAREZ AI: Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Int. J. Pharm. (2003) 263:123-132.
106. MERINO G, MOLINA AJ, GARCIA JL, PULIDO MM, PRIETO JG, ALVAREZ AI: Ginseng increases intestinal elimination of albendazole sulfoxide in the rat. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. (2003) 136:9-15.
107. BENNETT A, GUYATT H: Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol. Today (2000) 16:71-74.
108. HORTON J: Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology (2000) 121:S113-S132.
109. MCMANUS DP, ZHANG WB, LI J, BARTLEY PB: Echinococcosis. Lancet (2003) 362:1295-1304.
110. CHAVARRIA AP, SWARTZWELDER JC, VILLAREJOS VM, ZELEDON R: Mebendazole, an effective broad-spectrum anthelmintic. Am. J. Trop. Med. Hyg. (1973) 22:592-595.
111. DE CLERCQ D, SACKO M, BEHNKE J, GILBERT F, DORNY P, VERCRUYSSE J: Failure of mebendazole in treatment of human hookworm infections in die southern region of Mali. Am. J. Trop. Med. Hyg. (1997) 57:25-30.
112. ALBONICO M, BICKLE Q, RAMSAN M, MONTRESOR A, SAVIOLI L, TAYLOR M: Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull. World Health Organ. (2003) 81:343-352.
113. GROVER JK, VATS V, UPPAL G, YADAV S: Anthelmintics: a review. Trop. Gastroenterol. (2001) 22:180-189.
114. JANSSEN PA: The levamisole story. Prog. Drug Res. (1976) 20:347-383.
115. KOUASSI E, CAILLE G, LERY L, LARIVIERE L, VEZINA M: Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm. Drug Dispos. (1986) 7:71-89.
116. ADAMS JG: Pharmacokinetics of levamisole. J. Rheumatol. (1978) 4(Suppl.):137-142.
117. MILLER MJ: Use of levamisole in parasitic infections. Drugs (1980) 20:122-130.
118. GOIHMAN-YAHR M: Antihelmintic and antiparasitic drugs: unapproved uses or indications. Clin. Dermatol. (2000) 18:113-117.
119. AUSTIN WC, COURTNEY W, DANILEWICZ JC et al.: Pyrantel tartrate, a new anthelmintic effective against infections of domestic animals. Nature (1966) 212:1273-1274.
120. HOWES HL Jr, LYNCH JE: Anthelmintic studies with pyrantel. I. Therapeutic and prophylactic efficacy against the enteral stages of various helmindis in mice and dogs. J. Parasitol. (1967) 53:1085-1091.
121. AUBRY ML, COWELL P, DAVEY MJ, SHEVDE S: Aspects of the pharmacology of a new anthelmintic: pyrantel. Br. J. Pharmacol. (1970) 38:332-344.
122. FASANMADE AA, AKANNI AO, OLANIYI AA, TAYO F: Bioequivalence of pyrantel pamoate dosage forms in healthy human subjects. Biopharm. Drug Dispos. (1994) 15:527-534.
123. VILLAREJOS VM, ARGUEDAS-GAMBOAJA, EDUARTE E, SWARTZWELDER JC: Experiences with the anthelmintic pyrantel pamoate. Am. J. Trop. Med. Hyg. (1971) 20:842-845.
124. ISLAM N, CHOWDHURY NA: Mebendazole and pyrantel pamoate as broad-spectrum anthelmintics. Southeast Asian J. Trop. Med. Public Health (1976) 7:81-84.
125. KALE OO, BAMMEKE AO, NWANKWO EO: Field trials of pyrantel pamoate (Combantrin) in Ascaris, hookworm and Trichuris infections. Afr J. Med. Med. Sci. (1982) 11:23-31.
126. ANTHELMINTIC STUDY GROUP ON ENTEROBIASIS: A comparative evaluation of mebendazole, piperazine and pyrantel in threadworm infection. Indian Pediatr. (1984) 21:623-628.
127. REYNOLDSON JA, BEHNKE JM, PALLANT LJ et al.: Failure of pyrantel in treatment of human hookworm infections (Ancylostoma duodenale) in the Kimberley region of north west Australia. Acta Trop. (1997) 68:301-312.
128. ST GEORGIEV V: Pharmacotherapy of ascariasis. Expert Opin. Pharmacother. (2001) 2:223-239.
129. SWARTZWELDER C, MILLER JH, SAPPENFIELD RW: The treatment of cases of ascariasis with piperazine citrate with observations of the effect of the drug on other helminthiases. Am. J. Trop. Med. Hyg. (1955) 4:326-331.
130. FARID Z, BASSILY S, MINER WF, HASSAN A, LAUGHLIN LW: Comparative single/dose treatment of hookworm and roundworm infections with levamisole, pyrantel and bephenium. J. Trop. Med. Hyg. (1977) 80:107-108.
131. FUEHRMANN G: Zur Frage der Resorption und Ausscheidung von Piperazinsalzen. Z. Tropenmed. Tanasitol. (1957) 8:83-90.
132. SEFTEL HC, HEINZ HJ: Comparison of piperazine and tetramisole in the treatment of ascariasis. Br. Med. J. (1968) 4:93-95.
133. RIM HJ, HA JW, LEE JS, HYUN I, UH KB: Pyrantel embonate in mass treatment of ascariasis and comparison with piperazine adipate and santonin-kainic acid complex. Korean J. Parasitol. (1974) 12:141-146.
134. WHO: WHO model prescribing information. Drugs used in parasitic diseases (second edn), World Health Organization, Geneva (1995).
135. CAMPBELL WC, FISHER MH, STAPLEY EO, ALBERS-SCHONBERG G, JACOB TA: Ivermectin: a potent new antiparasitic agent. Science (1983) 221:823-828.
136. OTTESEN EA, CAMPBELL WC: Ivermectin in human medicine. J. Antimicrob. Chemother. (1994) 34:195-203.
137. BORSBOOM GJJM, BOATIN BA, NAGELKERKE NJD et al.: Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to climination/eradication in West-Africa. Filaria. J. (2003) 2:8.
138. GARDON J, GARDON-WENDEL N, NGANGUE D, KAMGNO J, CHIPPAUX J-P, BOUSSINESQ M: Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet (1997) 350:18-22.
139. REN HN, CHENG BZ, ZHUANG ZN: Experimental therapeutic efficacy of a new anti-hookworm drug - tribendimidin. Chin. J. Parasitol. Para. Dis. (1987) 5:262-264.
140. REN HN, YANG YQ, CHENG BZ et al.: Toxicity of tribendimidin, a new antihookworm drug. Chin. J. Parasitol. Para. Dis. (1988) 6:199-201.
141. XIAO SH, REN HN, DAI ZQ, YANG YQ, ZHANG CW: Light and electron microscopic observations on effects of tribendimidin on cuticle of Necator americanus and small intestinal mucosa of infected golden hamsters. Acta Pharmacol. Sin. (1989) 10:90-92.
142. XU SE, WU ZX, JIN LQ: Effect of tribendimidine on the ultrastructure of Ancylostoma duodenale and Necator americanus. Endemic Diseases Bulletin (2003) 18:12-13.
143. YANG YQ, YANG HZ, REN HN, CHENG BZ: Histological and histochemical effects of tribendimidine on Necator americanus. Acta Pharmacol. Sin. (1988) 9:264-267.
144. SUN FH, WU ZX, QIAN YX et al.: Field trials on the efficacy of tribendimidine against intstinal nematodiasis. Endemic Diseases Bulletin (1999) 14:75-78.
145. CAO HJ, SUN FH, QIAN YX et al.: Clinical observation on the efficacy of tribendimidine against hookworm infections. Chin. J. Parasit. Dis. Con. (2000) 13:184-186.
146. HUANG YX, ZHOU JX, XUE ZQ et al.: Clinical observations on the treatment of hookworm, Ascaris and Trichuris infection with oxibendazole. Chin. J. Parasitol. Para. Dis. (1990) 8:100-103.
147. HORTON J: Human gastrointestinal helminth infections: are they now neglected diseases? Trends Parasitol. (2003) 19:527-531.
148. LIM JK: Anthelminthic effect of oxantel and oxantel-pyrantel in intestinal nematode infections. Drugs (1978) 15(Suppl. 1):99-103.
149. PELDAN K, PITKANEN T: Treatment of Trichuris trichiura infection with a single dose of oxantel pamoate. Scand. J. Infect. Dis. (1982) 14:297-299.
150. ALBONICO M, BICKLE Q, HAJI HJ et al.: Evaluation of the efficacy of pyranteloxantel for the treatment of soil-transmitted nematode infections. Trans. R. Soc. Trop. Med. Hyg. (2002) 96:685-690.
151. GILLES HM, HOFFMAN PS: Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. (2002) 18:95-97.
152. ALBONICO M: Methods to sustain drug efficacy in helminth control programmes. Acta Trop. (2003) 86:233-242.
153. GEERTS S, GRYSEELS B: Drug resistance in human helminths: current situation and lessons from livestock. Clin. Microbiol. Rev. (2000) 13:207-222.
154. UTZINGER J, KEISER J, XIAO SH, TANNER M, SINGER BH: Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob. Agents Chemother. (2003) 47:1487-1495.
155. SHAW JR, BRAMMER KW: The treatment of experimental schistosomiasis with a combination of oxamniquine and praziquantel. Trans. R. Soc. Trop. Med. Hyg. (1983) 77:39-40.
156. PUGH RNH, TEESDALE CH: Synergy of concurrent low dose oxamniquine and praziquantel in schistosomiasis. Br. Med. J. (1983) 287:877-878.
157. CREASEY AM, TAYLOR P, THOMAS JEP: Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren. Cent. Afr. J. Med. (1986) 32:165-167.
158. ZWINGENBERGER K, NOGUEIRA QUEIROZ JA, POGGENSEE U et al.: Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil. Rev. Inst. Med. Trop. Sao Paulo (1987) 29:305-311.
159. XIAO SH, YOU JQ, MEI JY, GUO HF, JIAO PY, TANNER M: Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits. Parasitol. Int. (2000) 49:25-30.
160. UTZINGER J, CHOLLET J, YOU JQ, MEI JY, TANNER M, XIAO SH: Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop. (2001) 80:9-18.
161. DE CLERCQ D, VERCRUYSSE J, VERLÉ P, KONGS A, DIOP M: What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? Trop. Med. Int. Health (2000) 5:744-746.
162. MANI TR, RAJENDRAN R, MUNIRATHINAM A et al.: Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India. Trop. Med. Int. Health (2002) 7:541-548.
163. BELIZARIO VY, AMARILLO ME, DE LEON WU, DE LOS REYES AE, BUGAYONG MG, MACATANGAY BJ: A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull. World Health Organ. (2003) 81:35-42.
164. BEACH MJ, STREIT TG, ADDISS DG, PROSPERE R, ROBERTS JM, LAMMIE PJ: Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am. J. Trop. Med. Hyg. (1999) 60:479-486.
165. SIRIVICHAYAKUL C, POJJAROEN-ANANT C, WISETSING P et al.: A comparative trial of albendazole alone versus combination of albendazole and praziquantel for treatment of Trichuris trichiura infection. Southeast Asian J. Trop. Med. Public Health (2001) 32:297-301.
166. MOHAMED AE, YASAWY MI, AL KARAWI MA: Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology (1998) 45:1690-1694.
167. SHIELD J: A study of the effectiveness of mebendazole and pyrantel pamoate as a combination anthelmintic in Papua New Guinean children. P. N. G. Med. J. (1985) 28:41-44.
168. WHO: The world health report 2003: shaping the future. World Health Organization, Geneva (2003).
169. ANDREWS P: A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. Arzneimittelforschung (1981) 31:538-541.
170. LI SW, WU LJ, LIU ZD et al.: Studies on prophylactic effect of artesunate on schistosomiasis japonica. Chin. Med. J. (1996) 109:848-853.
171. DE CLERCQ D, VERCRUYSSE J, VERLÉ P, NIASSE F, KONGS A, DIOP M: Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:90-91.
172. PENE P, VINCENTELLI JM, SOULA G, DELMONT J, ROSSIGNOL JF: Treatment of intestinal nematode infections with albendazole. Preliminary results. Bull. Soc. Pathol. Exot. Filiales (1981) 74:590-594.
173. BELL WJ, NASSIF S: Comparison of pyrantel pamoate and piperazine phosphate in the treatment of ascariasis. Am. J. Trop. Med. Hyg. (1971) 20:584-588.
174. WU LJ, LI SW, XUAN YX et al.: Field application of artesunate in prophylaxis of schistosomiasis: an observation of 346 cases. Chin. J. Schisto. Con. (1995) 7:323-327.
175. ZHANG SJ, LIN DD, LIU YM et al.: Clinical trials on preventive effect of artesunate on schistosomiasis japonica. Mod. Diagn. Treat. (2000) 11:68-72.
176. TIAN ZY, LIU DS, XIAO ZW et al.: A cost-effect study of artesunate in the prophylaxis of schistosomiasis in an endemic area. Chin. J. Schisto. Con. (2001) 13:299-300.
177. XU MS: The effect analysis of using artesunate to prevent schistosome infection in the field. Chin. J. Parasit. Dis. Con. (2001) 14:26-27.
178. LU GY, LIN GJ, SUN MX, CUI JF, WU QZ, S: LJ. Probe on scheme with oral artesunate protecting people from infection of schistosome. Chin. J. Parasit. Dis. Con. (2000) 13:212-214.
179. LI HY, LIU ZD, HU LS et al.: Observation on the prevention of schistosomiasis japonica by administration of artesunate long-term. Chin. J. Parasit. Dis. Con. (1999) 12:214-215.
180. XU MS, ZHANG SQ, LI SW et al.: Field application of oral artesunate for preventing Schistosoma japonicum infection. Chin. J. Parasitol. Para. Dis. (1999) 17:241-243.
181. TIAN ZY, XIAO SH, XIAO JW et al.: Reduction of Schistosoma japonicum infection in an endemic area in islet with embankment after prophylaxis with oral artemether throughout the transmission season. Chin. J. Parasitol. Para. Dis. (1997) 15:208-211.
182. WANG JL, XIAO SH, YANG Z et al.: Effect of oral artemether in controlling schistosomiasis in Yunnan mountainous endemic area. Chin. J. Parasitol. Para. Dis. (1997) 15:138-142.
183. XIAO SH, WANG JL, WANG CZ et al.: Protection of the residents hom schistosome infection using oral artemether in mountainous endemic area. Chin. J. Parasitol. Para. Dis. (1996) 14:11-14.
184. XU MS, XIAO SH, SONG Q et al.: Observation on the effect of artemether on controlling schistosomiasis japonica in an endemic area of marshland. Chin. J. Parasitol. Para. Dis. (1997) 15:212-215.
185. XIAO SH, SHI ZG, ZHUO SJ et al.: Field studies on the preventive effect of oral artemether against schistosomal infection. Chin. Med. J. (1996) 109:272-275.
186. SONG Y, XIAO, SH, WU W et al.: Preventive effect of artemether on schistosome infection. Chin. Med. J. (1998) 111:123-127.
187. INYANG-ETOH PC, EJEZIE GC, USEH MF, INYANG ETOH EC: Efficacy of artesunate in the treatment of urinary schistosomiasis in an endemic community in Nigeria. Ann. Trop. Med. Parasitol. (2004) (In Press).